AAVrh74.tMCK.NT-3 Surrogate Gene Therapy in a Mouse Model of CMT2A.

Burcak Ozes, Lingying Tong, Kyle Moss, Morgan Myers, Israel Ndengabaganizi, Zarife Sahenk

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Burcak OzesCenter for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.

Lingying TongCenter for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.

Kyle MossCenter for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.

Morgan MyersCenter for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.ORCID 0000-0002-9136-7128

Israel NdengabaganiziDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.

Zarife SahenkCenter for Gene Therapy, The Abigail Wexner Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.ORCID 0000-0003-2974-3943

Funding

Sarepta Therapeutics (United States) GR001616

6 · The paper itself

Abstract

Mutations in the

Indexed as

Charcot-Marie-Tooth DiseaseDependovirusGenetic TherapyNeurotrophin 3AnimalsDisease Models, AnimalGene Therapy AgentsGenetic VectorsGTP PhosphohydrolasesMiceMitochondriaNerve Growth FactorsNeuromuscular JunctionGTP PhosphohydrolasesNerve Growth FactorsNeurotrophin 3neurotropin 3, mouseAAVadeno-associated virusCMT2AMFN2mitofusin 2neurotrophin-3NT-3

Identifiers

PMID41752078

DOI10.3390/ijms27041942

PMCPMC12940953

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.